Citrulinemia tipo I con insuficiencia hepática recurrente en un niño / Citrullinemia type I with recurrent liver failure in a child

La citrulinemia tipo I es un desorden autosómico recesivo causado por la mutación del gen ASS1, que expresa argininosuccinato sintetasa, enzima limitante del ciclo de la urea. Las variantes clásicas están asociadas con la forma neonatal/infantil, que llevan a hiperamoniemia y a la muerte si el tratamiento no es instaurado. Los síntomas iniciales de los trastornos del ciclo de la urea incluyen deterioro neurológico con leve o moderado daño hepático. Reportamos un caso de falla hepática recurrente en un lactante con diagnóstico de citrulinemia tipo I sin compromiso neurológico grave, que fue derivado a nuestro centro para trasplante hepático. La falla hepática aguda puede ser causada por una gran variedad de desórdenes, dentro de los que se incluyen errores congénitos del metabolismo. El tratamiento adecuado de los trastornos del ciclo de la urea y, en particular, la citrulinemia I puede evitar la necesidad de un trasplante.

Citrullinemia type I is an autosomal recessive disorder caused by mutation of the gene expressing ASS1 argininosuccinate synthetase, limiting enzyme of the urea cycle. The classic variants are associated with neonatal/infantile forms that cause hyperammonemia leading to death if treatment is not established. Initial symptoms of disorders of the urea cycle include neurological impairment with mild or moderate liver damage. We report a case of recurrent liver failure in an infant diagnosed with type I citrullinemia without severe neurological involvement that was referred to our center for liver transplantation. Acute liver failure can be caused by a wide range of disorders in which inborn errors ofmetabolism are included. Appropriate treatment of disorders of the urea cycle and in particular citrullinemia I can avoid the need for a transplant.

Liver failure following biliopancreatic diversions: a narrative review / Falência hepática após derivações biliopancreáticas: uma revisão narrativa

ABSTRACT CONTEXT AND OBJECTIVE: Occurrences of liver failure following jejunoileal bypass were extensively reported in the past and were one of the main factors that led to abandonment of this procedure. The newer predominantly malabsorptive procedures called biliopancreatic diversions (BPDs) have also been implicated in several cases of acute and subacute liver failure. The aim here was to review the current available evidence on occurrences of liver failure following BPDs. DESIGN AND SETTING: Narrative review; bariatric surgery service of a public university hospital. METHODS: A review of the literature was conducted through an online search of medical databases. RESULTS: Associations between BPDs and liver failure have only infrequently been reported in the literature. However, they appear to be more than merely anecdotal. The pathophysiological mechanisms remain obscure, but they seem to be related to rapid weight loss, protein malnutrition, deficits of hepatotrophic factors, high circulating levels of free fatty acids and bacterial overgrowth in the bypassed bowel segments. Reversal of the BPD may ameliorate the liver impairment. CONCLUSIONS: Although infrequent, liver failure remains a concern following BPDs. Careful follow-up is required in individuals who undergo any BPD.

RESUMO CONTEXTO E OBJETIVO: A ocorrência de falência hepática após a derivação jejunoileal foi extensivamente descrita no passado e foi um dos principais fatores que levaram ao abandono do procedimento. Os procedimentos predominantemente malabsortivos mais modernos, chamados de derivações biliopancreáticas, também já foram implicados em diversos casos de falência hepática aguda e subaguda. O objetivo foi revisar a atual evidência disponível sobre a ocorrência de insuficiência hepática após derivações biliopancreáticas. TIPO DE ESTUDO E LOCAL: Revisão narrativa; Serviço de Cirurgia Bariátrica de hospital universitário. MÉTODOS: Revisão da literatura conduzida por meio de pesquisa online de bancos de dados médicos. RESULTADOS: A associação entre derivações biliopancreáticas e falência hepática na literatura é infrequente. Entretanto, ela aparenta ser mais do que meramente anedótica. Os mecanismos fisiopatológicos continuam pouco compreendidos, mas parecem estar relacionados à rápida perda de peso, desnutrição proteica e déficit de fatores hepatotróficos, altos níveis circulantes de ácidos graxos livres e supercrescimento bacteriano em segmentos intestinais excluídos do trânsito. A reversão da cirurgia pode melhorar o comprometimento hepático. CONCLUSÕES: Embora infrequente, a falência hepática continua sendo preocupante após as derivações biliopancreáticas. Seguimento cuidadoso é mandatório em indivíduos submetidos a essas cirurgias.

Daño hepático agudo inducido por claritromicina. A propósito de un caso / Acute liver injury induced by clarithromycin, case report

Introducción: El daño hepático por fármacos es una lesión secundaria al uso de medicamentos. Posee una baja incidencia, representando la causa más común de muerte por falla hepática aguda. Es importante el diagnóstico y tratamiento precoz para evitar resultados desfavorables. Presentación del caso: Mujer de 73 años, con antecedentes de Hipertensión arterial en tratamiento, colecistectomizada; cursó neumonía adquirida en la comunidad de presentación atípica en tratamiento con claritromicina 500mg/12 horas y al cuarto día de tratamiento presentó ictericia, coluria, hipocolia y astenia. Al examen físico presentó dolor a palpación en hemiabdomen derecho y hepatomegalia. Los exámenes en urgencias mostraron una marcada alteración de las pruebas hepáticas, con leucocitos de 9.020/mm3 y 8% de eosinófilos. Se solicitó ecotomografía abdominal que no evidenció obstrucción de vía biliar. Durante la hospitalización se descartó serología para Virus Hepatitis A, B, C, Epstein Barr, Citomegalovirus y Virus de la Inmunodeficiancia Humana (VIH), junto con un perfil inmunológico no patológico. Se complementó con colangioresonancia que no evidenció obstrucción de la vía biliar, por lo que se indicó biopsia hepática que concluyó "daño hepático secundario a fármacos''. Se suspendió claritromicina, evolucionando favorablemente dándose de alta al séptimo día. Discusión: La claritromicina es un antibiótico usado ampliamente para tratar las infecciones bacterianas, sin embargo, es capaz de inducir daño hepático. El diagnóstico del daño hepático por fármacos es difícil, requiriéndose alto índice de sospecha, en donde las manifestaciones clínicas, la eosinofilia y el descarte de otras patologías son fundamentales para plantear el diagnóstico.

Introduction: Drug induced liver injury (DILI), is a drug hepatotoxicity, with low incidence. However represents the most common cause of death secondary to acute liver failure. Assertive diagnosis and early treatment is important to avoid adverse results. Case report: A 73-year-old woman, with arterial hypertension and cholecystectomy, who suffered community acquired pneumonia with atypical presentation, was treated with clarithromycin 500 mg twice a day. She manifested jaundice, choluria, hipocholia and fatigue after the fourth day in treatment. Additional, physical examination: at palpation showed right and upper abdominal pain, and hepatomegaly. During the emergency room, laboratory tests showed significant alterations in liver function. Total leukocyte count 9020 with 8% eosinophils. Abdominal ultrasound was negative for biliary obstruction. During hospitalization, markers for autoimmune liver disease were non pathological, and viral serologies (Hepatitis A, B, C viruses, Epstein Barr, Cytomegalovirus and Human immunodeficiency virus) were negative. Biliary obstruction was negative according Magnetic resonance cholangiopancreatography. Liver biopsy showed "drug induced liver injury". Clarithromycin was suspended, and the patient achieved clinical improvement and she was discharge at the 7th day. Discussion: Clarithromycin is an antibiotic widely used for several bacterial infections, capable of induced hepatotoxicity. Diagnosis of DILI is difficult, that requires high index of clinical suspicion. Clinical manifestations, eosinophilia and diferential diagnoses are key for an assertive diagnosis

Post-Acute Coronary Syndrome Alcohol Abuse: Prospective Evaluation in the ERICO Study / Abuso de Álcool após Síndrome Coronariana Aguda: Avaliação Prospectiva no Estudo ERICO

Background: Some studies have indicated alcohol abuse as one of the contributors to the development of cardiovascular disease, particularly coronary heart disease. However, this relationship is controversial. Objective: To investigate the relationship between post-acute coronary syndrome (ACS) alcohol abuse in the Acute Coronary Syndrome Registry Strategy (ERICO Study). Methods: 146 participants from the ERICO Study answered structured questionnaires and underwent laboratory evaluations at baseline, 30 days and 180 days after ACS. The Alcohol Use Disorders Identification Test (AUDIT) was applied to assess harmful alcohol consumption in the 12 months preceding ACS (30 day-interview) and six months after that. Results: The frequencies of alcohol abuse were 24.7% and 21.1% in the 12 months preceding ACS and six months after that, respectively. The most significant cardiovascular risk factors associated with high-risk for alcohol abuse 30 days after the acute event were: male sex (88.9%), current smoking (52.8%) and hypertension (58.3%). Six months after the acute event, the most significant results were replicated in our logistic regression, for the association between alcohol abuse among younger individuals [35-44 year-old multivariate OR: 38.30 (95% CI: 1.44-1012.56) and 45-54 year-old multivariate OR: 10.10 (95% CI: 1.06-96.46)] and for smokers [current smokers multivariate OR: 51.09 (95% CI: 3.49-748.01) and past smokers multivariate OR: 40.29 (95% CI: 2.37-685.93)]. Conclusion: Individuals younger than 54 years and smokers showed a significant relation with harmful alcohol consumption, regardless of the ACS subtype. .

Fundamento: Alguns estudos identificaram que o abuso de álcool contribui para o desenvolvimento de doença cardiovascular, em particular doença arterial coronariana. Tal relação, no entanto, é controversa. Objetivo: Investigar a relação entre abuso de álcool após síndrome coronariana aguda (SCA) na Estratégia de Registro de Insuficiência Coronariana (ERICO). Métodos: 146 participantes do ERICO responderam questionários estruturados e foram submetidos a avaliações laboratoriais nas condições basais e 30 dias e 180 dias após SCA. Aplicou-se o Questionário AUDIT (Alcohol Use Disorders Identification Test) para avaliar o consumo prejudicial de álcool nos 12 meses anteriores à SCA (entrevista 30 dias após a SCA) e seis meses após a SCA. Resultados: As frequências de abuso de álcool foram 24,7% e 21,1% nos 12 meses anteriores à SCA e seis meses após, respectivamente. Os fatores de risco cardiovascular mais significativos associados com alto risco de abuso de álcool 30 dias após o evento agudo foram: sexo masculino (88,9%), tabagismo atual (52,8%) e hipertensão (58,3%). Seis meses após o evento agudo, os resultados mais significativos foram replicados em regressão logística para a associação de abuso de álcool e indivíduos mais jovens [35-44 anos, RC multivariada: 38,30 (IC 95%: 1,44-1012,56); e 45-54 anos, RC multivariada: 10,10 (IC 95%: 1,06-96,46)] e fumantes [fumantes atuais, RC multivariada: 51,09 (IC 95%: 3,49-748,01); e ex-fumantes, RC multivariada: 40,29 (IC 95%: 2,37-685,93)]. Conclusão: Indivíduos com menos de 54 anos e fumantes apresentaram uma significativa relação com consumo prejudicial de álcool, a despeito do subtipo de SCA. .

Liver dysfunction induced by systemic hypersensitivity reaction to lamotrigine: case report

Lamotrigine is an anticonvulsant drug used to treat partial and generalized seizure disorders. Hypersensitivity to lamotrigine usually causes mild symptoms such as fever, rash, and slight invasion of internal organs. However, a 33-year-old male patient who was admitted with Stevens-Johnson syndrome after taking lamotrigine for 15 days experienced hepatic failure and died 5 days after admission. This case demonstrates the importance of realizing that lamotrigine can lead to fatal hepatic failure, and that tests for the normal liver function should be performed when administering lamotrigine.

Falla hepática fulminante por virus Epstein Barr: rol de los corticoides: caso clínico / Epstein Barr virus and acute liver failure: role of steroids: clinical case

La falla hepática fulminante (FHF) debida a Virus Epstein Barr (VEB) es poco frecuente en inmunocompetentes. La utilidad de los esteroides en este cuadro no ha sido definida y permanece muy controversial. Objetivo: Reportar el caso de una paciente con mononucleosis infecciosa por VEB que presenta FHF y es tratada con corticoides. Caso clínico: Escolar con cuadro de 2 sem de síntomas respiratorios altos, fiebre, adenopatías, con ictericia y orina oscura. Bilirrubina total: 9; B. Directa: 6,3; Fosfatasas Alcalinas: 523; GOT: 7.527; GPT: 6.537; Protrombina (PT): 17 por ciento INR: 4,7; Amonio 510 y glicemia 33. Ecografía abdominal hígado normal y esplenomegalia. Monotest Positivo. Se transfirió a centro de trasplante hepático (TH). Laboratorio de ingreso PT 21 por ciento; bilirrubina en 9,8; GOT 2717; GPT 3716 y amonio 177. EEG con enlentecimiento difuso compatible con encefalopatía grado 1. IgM VEB positiva, descartándose otras etiologías. Se activó para TH por FHF y mientras se administró Metilprednisolona por 5 días. Evolucionó con normalización de las pruebas hepáticas y mejoría clínica. Conclusión: En este caso el uso de esteroides se asoció a una rápida y favorable respuesta tanto clínica como de laboratorio sin presentar efectos secundarios negativos. Al igual que en otras presentaciones de infección grave por VEB, debiera considerarse el uso de esteroides en FHF por VEB.

Acute liver failure (ALF) due to Epstein Barr Virus (EBV) is rare in immunocompetent patients. The role of steroids in this case is not well defined and remains controversial. Case report: 7 years old female presenting with unspecific respiratory symptoms for 2 weeks, fever, lymphadenopathy, jaundice and dark brown urine. Total bilirubin: 9 and direct: 6.3, alkaline phosphatases: 523; AST: 7.527, ALT: 6.537; Prothrombin (PT): 17 percent, INR: 4.7; ammonium 510 and glucose 33. Abdominal ultrasound: normal liver and splenomegaly. Monotest Positive. She was transferred to a liver transplant centre (LT). Lab results at admission: PT 21 percent, bilirubin 9.8, AST 2717, ALT 3.716 and ammonium 177. EEG with diffuse and slowing conductivity consistent with encephalopathy. Positive IgM EBV, other aetiologies were ruled out. She was activated for LT due to ALF and while in waiting list methylprednisolone was administered for 5 days. She evolved with normalization of liver tests and clinical improvement. Conclusion: In this case the use of steroids was associated with a rapid and favourable clinical and laboratory response without negative side effects. As in other presentations of serious infection by EBV, should consider the use of steroids in ALF due to EBV.

Feasibility and Efficacy of Stereotactic Ablative Radiotherapy for Barcelona Clinic Liver Cancer-C Stage Hepatocellular Carcinoma

The purpose of this study was to assess the feasibility and efficacy of stereotactic ablative radiotherapy (SABR) for liver tumor in patients with Barcelona Clinic Liver Cancer (BCLC)-C stage hepatocellular carcinoma (HCC). We retrospectively reviewed the medical records of 35 patients between 2003 and 2011. Vascular invasion was diagnosed in 32 patients, extrahepatic metastases in 11 and both in 8. Thirty-two patients were categorized under Child-Pugh (CP) class A and 3 patients with CP class B. The median SABR dose was 45 Gy (range, 30-60 Gy) in 3-5 fractions. The median survival time was 14 months. The 1- and 3-yr overall survival (OS) rate was 52% and 21%, respectively. On univariate analysis, CP class A and biologically equivalent dose > or = 80 Gy10 were significant determinants of better OS. Severe toxicity above grade 3, requiring prompt therapeutic intervention, was observed in 5 patients. In conclusion, SABR for BCLC-C stage HCC showed 1-yr OS rate of 52% but treatment related toxicity was moderate. We suggest that patients with CP class A are the best candidate and at least SABR dose of 80 Gy10 is required for BCLC-C stage.

Familial systemic lupus erythematosus with hypercalcemia.

An 8-yr-old girl with familial systemic lupus erythematosus and several severe manifestations, including persistent thrombocytopenia, rapidly progressive renal failure and hepatic failure is described. The course was complicated by the occurrence of hypercalcemia, hypophosphatemia and elevated levels of parathormone, an association not previously reported in children.

Transplante de fígado para falência hepática fulminante / Liver transplant for fulminant hepatic failure

A falência hepática fulminante (FHF) é uma síndrome clínica com alta morbidade e mortalidade. A disfunção de múltiplos órgãos apresentada pelos pacientes com FHF é um dos mais intrigantes problemas do manejo em medicina clínica e requer cooperação entre intensivistas, neurologistas, hepatologistas e cirurgiões de transplante. A única intervenção terapêutica que provê benefício definitivo nos pacientes com falência hepática aguda avançada é o transplante de fígado de emergência.

The fulminant hepatic failure (FHF) is a clinical syndrome associated with high morbidity and mortality. The multiorgan dysfunction presented by patient with FHF is one of the most challenging management problems in clinical medicine and require very close cooperation in clinical medicine, the meurologist, and the hepatologist and transplant surgeon's. The only therapeutic intervention of proven benefit for patients with advanced acute liver failure is the emergency liver transplantation. We performed a retrospective analysis of patients with FHF and submited for liver transplantation at the Oswaldo Cruz University Hospital, Pernambuco University.

Atypical relapsing course of Kawasaki disease with hemorrhagic serous effusions and hepatic dysfunction.

Kawasaki disease (KD) is a multisystem vasculitis of childhood with cardiac, renal, pulmonary and neurological complications. Hemorrhagic serous effusions, liver dysfunction and relapsing course in spite of treatment are rare. We report an atypical case of KD with a relapsing course, hemorrhagic effusions and hepatic dysfunction, that required two repeated courses of intravenous immunoglobulin (IVIG) and methylprednisolone.

Liver involvement in celiac disease.

Celiac disease may present as a cryptogenic liver disorder being found in 5-10 % of patients with a persistent and cryptogenetic elevation of serum aminotransferase activity. In fact, a wide spectrum of liver injuries in children and adults may be related to CD and in particular: (1) a mild parenchymal damage characterised by absence of any clinical sign or symptom suggesting a chronic liver disease and by non-specific histological changes reversible on a gluten-free diet; (2) a chronic inflammatory liver injury of autoimmune mechanism, including autoimmune hepatitis, primary sclerosing cholangitis and primary biliary cirrhosis, that may lead to fibrosis and cirrhosis, generally unaffected by gluten withdrawal and necessitating an immunosuppressive treatment; (3) a severe liver failure potentially treatable by a gluten-free diet. Such different types of liver injuries may represent a spectrum of a same disorder where individual factors, such as genetic predisposition, precocity and duration of exposure to gluten may influence the reversibility of liver damage. A rigorous cross-checking for a asymptomatic liver damage in CD individuals and conversely, for CD in any cryptogenic liver disorder including end-stage liver failure is recommended.

A Case of Multiple Organ Failure due to Heat Stoke Following a Warm Bath

Heat stroke is a potentially fatal disorder that's caused by an extreme elevation in body temperature. We report here an unusual case of multiple organ failure that was caused by classical, nonexertional heat stroke due to taking a warm bath at home. A 68 year old diabetic man was hospitalized for loss of consciousness. He was presumed to have been in a warm bath for 3 hrs and his body temperature was 41 degrees C. Despite cooling and supportive care, he developed acute renal failure, disseminated intravascular coagulation (DIC) and fulminant liver failure. Continuous venovenous hemofiltration was started on day 3 because of the progressive oligouria and severe metabolic acidosis. On day 15, septic ascites was developed and Acinetobacter baumanii and Enterococcus faecium were isolated on the blood cultures. In spite of the best supportive care, the hepatic failure and DIC combined with septic peritonitis progressed; the patient succumbed on day 25.

Effects of ultrasound on liver

The unicellular organisms and small fish were killed when Ultrasound was first used. Exposure of Rat's liver to varying ultrasound frequencies and time intervals had produced damage ranging from perilobular necrosis to centrilobular damage with lymphocytic infiltration. Keeping in view the growing application trend of diagnostic ultrasound in medicine, its effect's on rabbit's liver were studied. Fifty rabbits with 6501350 gm gross body weight, were studied in five groups. Group I was control and Groups II-V were exposed to an ultrasound frequency of 5 MHz, intensity 100db for 5 minutes daily for 5,10,15 and 30 days. On completion of each exposure, livers were dissected out and examined macroscopically. Macroscopically liver revealed subcapsular hemorrhages and 1-3 mm size connective tissue nodules with solid walls and soft necrotic center. The tissues were processed and stained by heamotoxyllin, eosin and silver impregnation method. The microscopic examination revealed cavitational spaces [dilated sinuses], swollen hepatocytes with large clear spaces, lymphocytic infiltration, perilobular [triad], centrilobular distortion progressing in intensity in groups II to IV. Maximum distortion with necrosis and fibrosis was noted in group V. The findings of the current study reveal that ultrasound may have side effects if used repeatedly especially when for longer duration

A Case of Fulminant Hepatic Failure in Wilson's Disease Combined with Systemic Lupus Erythematosus / 대한간학회지

Patients with systemic lupus erythematosus (SLE) have a chance of developing liver involvement in their lifetime. The main cause of liver involvement in SLE patients is previous treatment with hepatotoxic drugs or hepatotropic viral hepatitis. Wilson's disease is a hereditary disorder and is usually diagnosed in patients presenting either neuropsychiatric disorders or manifestations related to chronic liver disease. Fulminant hepatic failure as the initial manifestation of Wilson's disease is rare. The relationship between systemic lupus erythematosus and Wilson's disease has not been established. We report a case of a 12-year-old girl with SLE who presented fulminant hepatic failure as an initial manifestation of Wilson's disease. The diagnosis was established with decreased serum ceruloplasmin level and the presence of Kayser-Fleischer ring. We treated with repeated plasma exchange. Despite repeated plasma exchange she died of multi-organ failure on the 16th hospital day. Considering this case, Wilson's disease should be considered as a cause of fulminant hepatic failure, especially in juvenile age cases.

Clinical implications of hepatitis G virus (HGV) infection in patients of acute viral hepatitis & fulminant hepatic failure.

BACKGROUND & OBJECTIVES: Viral hepatitis is a major public health problem especially in developing countries such as India. Hepatitis viruses A, B, C, D and E are all well characterized and molecularly defined agents with unequivocal association with human liver disease but there is evidence of hepatitis in humans caused by certain transmissible agents which cannot be classified with the above hepatotoric viruses. The role of recently discovered hepatitis G virus (HGV/GBV-C) as an independent heaptitis agent is controversial. Recently, we have shown a relatively high frequency of HGV infection in fulminant hepatic failure but the virus was often detected in co-infection with hepatitis B or E virus. The present study has therefore been carried out to evaluate the clinical significance of HGV infection in acute viral hepatitis (AVH) and fulminant hepatic failure (FHF) through follow up of HGV positive patients till their clinical and biochemical recovery. METHODS: The study included 50 patients comprising 35 of AVH and 15 of FHF. These patients were evaluated on the basis of history, physical examination, liver function profile and serological markers for hepatitis A, B, C and E. Those patients serologically negative for HBV and HCV infection were further screened for HBV DNA and HCV RNA by PCR. All the samples were screened for presence of HGV-RNA by RT-PCR using inner and outer primers sequences selected from NS3 helicase region of the HGV genome. FHF patients who died were subjected to postmortem liver biopsy and these biopsy specimens were also screened for HGV-RNA. Repeat detection of HGV-RNA was done after clinical and biochemical recovery of the patients. RESULTS: Of 35 AVH patients, HGV infection was detected in 5 patients (14.3%) while 4 of 15 patients (26.6%) in the FHF group were positive for HGV-RNA. Five HGV positive AVH patients were followed till clinical and biochemical recovery and all of them tested positive for HGV-RNA at follow up (6 weeks to 6 months). Out of 4 HGV positive FHF patients, only one survived and his repeat sample after clinical and biochemical recovery tested positive for HGV-RNA. INTERPRETATION & CONCLUSIONS: The results suggest that HGV infection does occur in patients of AVH and FHF and HGV viraemia persists for a long time even after clinical and biochemical recovery. These observations point towards a possible non-pathogenic role of hepatitis G virus infection.

Falla hepatica fulminante: forma atipica de presentacion de insuficiencia cardiaca / Fulminant hepatic failure: atypical form of cardiac failure presentation

La insuficiencia cardíaca puede presentar como manifestación clínica la enfermedad hepática congestiva. En el shock cardiogénico puede aparecer falla hepática aguda por isquemia hepática. Presentamos una paciente que con antecedentes de insuficiencia cardíaca crónica ingresa a nuestro servicio por presentar mal estado general asociado a deterioro progresivo del hepatograma, del tiempo de protrombina y de la función renal. Las serologías virales y los autoanticuerpos fueron negativos. No tenía antecedentes de contacto con hepatotóxicos. En su evolución presentó encefalopatía sin evidencias iniciales de shock. Al cuarto día de internación presenta shock cardiogénico, con manifestaciones del laboratorio compatibles con isquemia y congestión hepáticas. La paciente fallece 24 horas después. La histología demostró cambios compatibles con isquemia hepática. Se han descripto varios casos de hepatopatías crónicas sin causa evidente que resultaron ser manifestaciones secundarias a enfermedades cardiológicas, especialmente pericarditis constrictiva o miocarditis restrictivas. En este caso la paciente presentó falla hepática aguda sin evidencia inicial de mayor deterioro de su cardiopatía previa. Con este caso queremos destacar la importancia de las causas cardiológicas como probables etiologías de hepatopatías sin causa aparente.